Titan Pharmaceuticals (NASDAQ:TTNP) issued its quarterly earnings data on Monday. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.01), MarketWatch Earnings reports. Titan Pharmaceuticals had a negative net margin of 351.69% and a negative return on equity of 1,144.30%.
Titan Pharmaceuticals stock traded down $0.00 during trading hours on Tuesday, hitting $0.11. The stock had a trading volume of 79,467 shares, compared to its average volume of 14,648,305. The business’s 50 day simple moving average is $0.14 and its 200-day simple moving average is $0.24. Titan Pharmaceuticals has a one year low of $0.09 and a one year high of $0.55. The stock has a market cap of $22.86 million, a price-to-earnings ratio of -0.30 and a beta of 0.90. The company has a quick ratio of 1.59, a current ratio of 1.79 and a debt-to-equity ratio of 2.14.
Separately, Maxim Group downgraded shares of Titan Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a report on Friday, August 14th.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism.
See Also: Why is cost of goods sold important?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.